Warsaw (OTE) – Polpharma Group has completed the acquisition of the
Romanian
pharmaceutical company Biofarm. The transaction is a clear step in
the execution of the Group’s growth strategy and strengthens its
position in Central and Eastern Europe. With Biofarm joining the
Group, Polpharma is expanding the scale of its operations,
reinforcing its presence in key regional markets, and creating new
opportunities to improve patients’ access to trusted medicines across
the region and beyond.
“Poland remains the place from which we define the strategic
direction of our Group and pursue our ambitious international growth
plans. The acquisition of Biofarm confirms our long-term commitment
to building a strong, multiregional pharmaceutical organization. We
are a privately owned company with an entrepreneurial gene: we act
responsibly, move with speed, and believe in cooperation. This is how
we want to grow – always with patients’ needs at the center and with
a tangible contribution to improving access to medicines and
strengthening pharmaceutical security across Central and Eastern
Europe,” says Sebastian Szymanek, CEO of Polpharma Group .
Combining the strengths of both organizations creates greater
opportunities to develop and provide patients with access to a
broader portfolio of trusted products. Biofarm’s strong position in
Romania and Polpharma’s regional footprint create a platform to
support the continued availability of Biofarm products in Romania,
while also opening potential for their presence in additional
markets.
Biofarm is one of the most recognized pharmaceutical
manufacturers in Romania. The company has operated continuously since
1921, owns two manufacturing facilities, and exports its products to
countries across Europe and Asia. Its portfolio includes more than
200 products spanning dozens of therapeutic areas.
“Joining Polpharma Group opens up new opportunities for Biofarm’s
future development. By combining the experience of our local team,
deep market knowledge, and the strength of the Group, we will be able
to develop our product portfolio even more effectively, explore
opportunities for Biofarm products in other markets, and create
greater value for patients and business partners,” says Tamás Uri,
General Manager, CEE Region at Polpharma Group .
In the coming phases, the Group will focus on leveraging the
synergies resulting from the combination of competencies, product
portfolios, and the experience of both organizations.